Renaud Dehareng

Renaud Dehareng

Group Chief Executive Officer

Renaud became CEO in 2012, with a vision of increasing profitability and developing Curium into a global leader in nuclear medicine. He achieved this goal with great success, turning the organization into a larger, more vertically-integrated institution with a global reach

Renaud is now leveraging Curium’s unique global infrastructure and proven industry experience to serve its nuclear medicine clients with an emphasis on compliance, service reliability, operational excellence and new product development.

One of Renaud’s main achievements has been to pull together the best team of more than 2000 members worldwide to take Curium through its vision and strategy.

Renaud has been part of Curium and its predecessors’ companies since 2009. Prior to his current role, he was Group COO and CEO Europe. Previously, he served in Arthur Andersen’s strategic consulting division, which he joined after graduating from the UK’s Warwick Business School.

Renaud resides in Belgium with his wife and three children. In his spare time, he competes in triathlons and enjoys kite surfing.

Xavier Defourt

Xavier Defourt

Chief Legal Officer

As Chief Legal Officer, Xavier leads Curium’s legal team.

In this role, he and his team support Curium’s operations in their day-to day-legal questions and challenges, ensure corporate housekeeping of all entities, act as Secretary to the Board and Committees of the parent entities, supervise compliance with Group policies, ensure proper insurance coverage of all activities and entities, and assist members of the Group Leadership Team in the Group’s M&A, CMO and in-licensing projects.

Xavier holds more than ten years’ experience working as Attorney at the Brussels Bar, followed by 15 years’ experience as Chief Legal Officer at Ion Beam Applications S.A., the Belgian listed company active in cyclotron manufacturing, proton-therapy and dosimetry, which owned IBA Molecular until 2012.

Xavier holds a Master-in-Law from the University of Louvain-la-Neuve, Belgium, and a Post Master in Economic Law from the University of Gent, Belgium. Married with three children, Xavier is a keen ultra-trail runner and mountain lover.

Ciril Faia

Ciril Faia


As CEO SPECT Europe, Ciril is responsible for Curium’s SPECT manufacturing operations in Saclay, France and in Petten, The Netherlands as well as SPECT commercial operations across France, Italy, Germany, and the Nordics. This includes both current SPECT product portfolio, Mo-99 production, as well as new initiatives such as the Group’s global Lu-177 production program.

Most recently, Ciril was Curium’s Chief Strategy Officer – a role he held since 2017 – where he led the Company’s ten-year strategic plan, new product development initiatives and the Group Investment Committee & Project Management Office.

Ciril has 20 years of experience in healthcare and strategy consulting, with a strong focus on growth strategy. Prior to his time at Curium, he served as Partner at one of the world’s leading management consultancies. Ciril holds a master’s degree from ESSEC Business School (Paris), and is married with four children. He is a keen marathon runner and acts as an active Board Member of ‘Petits Princes’, a wish-granting charity for critically-/chronically-ill children.

Rudolf van Houten

Group Chief Financial Officer

Rudolf is the Group Chief Financial Officer with responsibility for Global Finance, Shared Services and IT.  He is a member of Curium’s Executive Committee.  Rudolf holds more than 25 years of finance experience gained working in the U.S., Europe and Asia.

Prior to joining Curium, Rudolf was Global Head of Group Finance for Takeda Pharmaceuticals based in Tokyo, Japan.  Before that, he spent 10 years as Group CFO for Aysta LifeScience, a private equity sponsored company in the crop protection industry.

Rudolf graduated from the College of William and Mary, in Virginia with a BBA in Finance and holds an MBA from IMD in Lausanne, Switzerland.

Sakir Mutevelic MD, MSc

Chief Medical Officer

As Chief Medical Officer, Sakir leads Curium’s global medical strategy and clinical development for diagnostic and therapeutic radiopharmaceuticals.

In this role, he develops and leads the key Curium`s product pipeline growth initiatives, to drive product evolution and portfolio expansion across radiopharmaceutical diagnostics, companion diagnostics and therapeutics ensuring the Curium Group fulfills its mission “Life Forward” to transform and improve the disease management and patient lives. This includes managing and coordinating strategic partnerships, strategic clinical development planning and operational execution, managing the clinical aspects of regulatory strategies and interactions with health authorities, as well as supporting Curium`s strategic initiatives from medical and clinical development perspective. Sakir is a member of Curium’s Global Leadership Team.

Sakir has more than 25 years of professional experience in the pharmaceutical industry, with profound clinical experience and successful clinical development track of both new chemical and biological entities in oncology and hematology from early to late stage clinical development as well as global regulatory submissions and approvals. Prior to his time at Curium, he served in different strategic and operational functions with increasing responsibility at country, regional and global level, at Boehringer Ingelheim, Baxter, Baxalta, Shire, Servier and AAA/Novartis

Sakir holds a medical doctor degree and master degree in pharmacology and is married with two children. He is a keen alpine skier and passionate about the mountains and the environment since a young age.

Michael Patterson

North America Chief Executive Officer

Mike is Curium’s North America Chief Executive Officer. He has executive responsibility for the organization’s business in the region, across areas including Operations, Finance and Commercial, and is a member of Curium’s Executive Committee.

Mike joined Curium in October 2017 as VP of Marketing for North America.  He has 25 years of professional experience in the pharmaceutical industry, most recently with Mallinckrodt in various roles including Marketing, Chief of Staff to the President of Commercial, and Managed Care.  He also worked at Sanofi in commercial roles including Sales, Sales Leadership and Marketing.

Mike holds an MBA from Washington University in St. Louis and a BS from the University of Illinois and resides in St. Louis with his wife and daughter. Mike enjoys running and playing golf.

Chaitanya Tatineni

CEO International Markets Chief M&A Officer

Chaitanya is the CEO of Curium’s International Markets & Chief M&A Officer for the Group.   He leads Curium’s PET, SPECT and Therapy operations in international markets – outside of the US, Canada, and Western Europe – with a focus on building the Company’s presence in China and Japan. In his capacity as the Chief M&A Officer, Chaitanya is responsible for defining and executing the group’s inorganic growth initiatives, including M&A, in-licensing, and strategic collaborations. Chaitanya is a member of Curium’s Executive Committee.

Prior to joining Curium, Chaitanya had more than 11 years of professional experience in investment banking, and had executed more than 20 transactions for pharmaceuticals, diagnostics, and healthcare services clients across the US, Europe, and Asia. He has previously worked for the healthcare investment banking teams at Jefferies, Bank of America Merrill Lynch, and ABN AMRO banks in both London and Hong Kong.

Chaitanya holds an MBA from the Indian Institute of Management Ahmedabad and a bachelor’s degree in Electronics and Communication Engineering from the Indian Institute of Technology, Kharagpur.

Benoit Woessmer

Benoît Woessmer

PET Europe Chief Executive Officer

Benoît is PET Europe Chief Executive Officer and leads Curium’s operational activities across Europe. In this role, he is responsible for all commercial activities, as well as managing the PET facility network of Curium in UK and the rest of Europe.

His strategic focus is to drive the Company’s growth across Europe and especially in the UK PET market, as well as ensure the region’s PET business maintains a high-level of service quality to Curium’s customers.

Benoît has more than 20 years of experience in the medical imaging field, in both radiology and nuclear medicine. Prior to joining IBA Molecular (now Curium), Benoît served as Contrast Media Business Unit Director for Covidien Germany.

Benoît holds a master’s degree in Biology from UPMC (Paris), and a master’s degree in Health Law from Descartes University (Paris). He is married with two children.

Mathilde Marret

VP Group Strategy

As Vice President Group Strategy, Mathilde is responsible for the Company’s strategic planning, manufacturing and distribution partnerships, new product development, and inorganic initiatives. She has been a part of the Company’s strategy team since 2021 and assumed the role of Vice President in January 2023.

Mathilde has more than ten years of experience in corporate strategy. Prior to joining Curium, Mathilde was Principal at strategy consulting firm the Boston Consulting Group in Paris for five years where she supported investors in acquiring and growing healthcare businesses globally. Mathilde previously was a Consultant with Roland Berger Strategy Consultants for four years.

Mathilde holds a masters’ degree in Political Science from Institut d’Etudes Politiques de Lyon and Ecole Normale Supérieure Ulm, and a master’s degree in International Business from HEC Paris Business School. Based in Paris full-time, Mathilde is an avid outdoor enthusiast spending time hiking, climbing, mountaineering, and skiing.  

Paul Gronland

VP Project Management Office

As VP PMO, Paul is responsible for supporting Curium’s key growth initiatives across the group through the different strategic units. Prior to this role, Paul spent eight years across the Company in St. Louis, Missouri, Petten, The Netherlands, and Saclay, France where he was instrumental in driving the roll-out of many of Curium’s strategic and pharmaceutical production initiatives. Prior to this Paul spent three years with Curium’s main irradiation services provider in The Netherland at the Nuclear Research and Consultancy Group (NRG) where he developed his aptitude for running mission critical projects.

A seasoned project management professional with over 20 years of experience running complex high value projects, Paul adds considerable value to the Company by managing the technically and organizationally complex projects.

Born in the UK and raised in Cape Town, South Africa, Paul graduated in Engineering from the University of Port Elizabeth, South Africa. Post-graduation Paul spent ten years in the automotive sector developing his skills with Volkswagen and Honda. He is married with three daughters and is an avid yoga and outdoor pursuits enthusiast.